BioSpace News Archive

H3 Biomedicine Inc. today announced the addition of Richard Woodman, M.D. to its Board of Directors (“Board”).

ReCode Therapeutics today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today.

Equillium, Inc. announced that three abstracts were accepted for presentation at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.

Bluestar Genomics, Inc. today announced the appointment of David Mullarkey as chief executive officer, effective January 10.

Aptorum Group Limited, a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, non-small cell lung cancer and autoimmune diseases such as lupus, rheumatoid arthritis, inflammatory bowel diseases, etc.

Establishment Labs Inc. today reported preliminary unaudited revenue for the three months and fiscal year ended December 31, 2021.

Allogene Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on all of the Company’s AlloCAR T clinical trials.

Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy ® in Combination With KEYTRUDA ® in First-Line Metastatic Non-Small Cell Lung Cancer.

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced that it plans to participate in the following two dermatology conferences in January:

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40 th Annual J.P. Morgan Healthcare Conference.